Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Shinya Nakamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3263-7271; OpenAlex author ID A5038023303. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2021: 4 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 10

  1. Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights from a multicenter cohort study in Japan. Co-author DOI 10.1007/s00535-025-02340-x↗
  2. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15221-z↗
  3. Diagnostic Ability and Safety of Repeated Pancreatic Juice Cytology Using an Endoscopic Nasopancreatic Drainage Catheter for Pancreatic Ductal Adenocarcinoma: … Co-author DOI 10.3390/diagnostics13162696↗
  4. Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/jcm12196245↗
  5. Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.02.001↗
  6. Value of Dual-Energy Computed Tomography for Detecting Small Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002207↗
  7. The role of apparent diffusion coefficient value in the diagnosis of localized type 1 autoimmune pancreatitis: differentiation from pancreatic ductal adenocarc… Co-author DOI 10.1007/s00261-020-02907-7↗
  8. Extracellular volume fraction with MRI: As an alternative predictive biomarker to dynamic contrast-enhanced MRI for chemotherapy response of pancreatic ductal … Co-author DOI 10.1016/j.ejrad.2021.110036↗
  9. Adding Delayed Phase Images to Dual-Phase Contrast-Enhanced CT Increases Sensitivity for Small Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.20.25430↗
  10. Role of Endoscopic Ultrasonography and Endoscopic Retrograde Cholangiopancreatography in the Diagnosis of Pancreatic Cancer. Co-author DOI 10.3390/diagnostics11020238↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasutaka Ishii · 7 shared papers, 2021–2026 · strength 1.07
  2. Juri Ikemoto · 6 shared papers, 2021–2026 · strength 0.88
  3. Kenichiro Uemura · 4 shared papers, 2022–2026 · strength 0.71
  4. Tomofumi Tsuboi · 4 shared papers, 2021–2023 · strength 0.49
  5. Shin’ya Takahashi · 2 shared papers, 2024–2026 · strength 0.44
  6. Yosuke Fujisaki · 3 shared papers, 2021–2022 · strength 0.42
  7. Yoshihiko Fukukura · 3 shared papers, 2021–2022 · strength 0.42
  8. Takashi Yoshiura · 3 shared papers, 2021–2022 · strength 0.42
  9. Shiro Oka · 2 shared papers, 2023–2026 · strength 0.39
  10. Masanobu Yukutake · 2 shared papers, 2023–2026 · strength 0.39
  11. Atsushi Yamaguchi · 2 shared papers, 2023–2026 · strength 0.39
  12. Keiji Hanada · 2 shared papers, 2023–2026 · strength 0.39
  13. Tomoyuki Minami · 2 shared papers, 2023–2026 · strength 0.39
  14. Ryota Kawamura · 3 shared papers, 2021–2022 · strength 0.34
  15. Masaru Furukawa · 2 shared papers, 2022–2023 · strength 0.27
  16. Kazuaki Chayama · 2 shared papers, 2021 · strength 0.22
  17. Takumi Harada · 1 shared paper, 2024 · strength 0.20
  18. Yoshiaki Murakami · 1 shared paper, 2024 · strength 0.20
  19. Tatsuaki Sumiyoshi · 1 shared paper, 2024 · strength 0.20
  20. Kenjiro Okada · 1 shared paper, 2024 · strength 0.20
  21. Ryuta Shintakuya · 1 shared paper, 2024 · strength 0.20
  22. Kenta Baba · 1 shared paper, 2024 · strength 0.20
  23. Shinichi Hashimoto · 1 shared paper, 2022 · strength 0.15
  24. Hiroshi Kurahara · 1 shared paper, 2022 · strength 0.15
  25. Dominik Marcel Nickel · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.